Lupin Receives Single USFDA Observation at Goa Manufacturing Plant

Indian drugmaker Lupin Ltd. received one observation from the U.S. Food and Drug Administration (USFDA) for its manufacturing plant in Goa. The observation was issued during a routine inspection that evaluates compliance with Good Manufacturing Practices (GMP). The USFDA noted a single area that requires corrective action but did not raise any major safety concerns.

Lupin has previously complied with USFDA requirements for its other facilities, and the company has stated it will address the observation promptly. The observation is part of the agency’s ongoing oversight of foreign manufacturers supplying drugs to the United States.

The company’s spokesperson said that the observation does not affect the availability of its products in the U.S. market and that Lupin will submit a corrective action plan within the required timeframe.